Brought to you by

Labrys Biologics begins operations with $31mm Series A financing, migraine antibody from Pfizer
15 Apr 2013
Executive Summary
Lead investor venBio has teamed with Canaan Partners, InterWest Partners, Sofinnova Ventures, and one other undisclosed backer in the $31mm Series A financing for Labrys Biologics Inc., which has concurrently licensed from Pfizer the Phase I antibody RN307. Labrys will advance the candidate, which targets the calcitonin gene-related peptide (CGRP), into Phase II for chronic migraine later this year. VenBio's managing director Corey Goodman, PhD (also a former Pfizer exec), is Labrys' founder. Representatives from Canaan Partners, InterWest, and Sofinnova have joined the start-up’s board.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com